<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03861247</url>
  </required_header>
  <id_info>
    <org_study_id>KY-2018470</org_study_id>
    <nct_id>NCT03861247</nct_id>
  </id_info>
  <brief_title>Individualized Treatment of Hyperphosphatemia in Maintenance Hemodialysis Patients</brief_title>
  <official_title>Individualized Treatment of Hyperphosphatemia Based on Phosphate Balance in Maintenance Hemodialysis Patients: a Multicenter, Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chen Jing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Huadong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Tongji Hospital, Tongji University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research is designed as a prospective, randomized, controlled clinical trial without&#xD;
      blinding. A total of 116 participants with hyperphosphatemia will be enrolled from three&#xD;
      hemodialysis center (56 from Huashan Hospital, 30 from Huadong Hospital and 30 from Tongji&#xD;
      Hospital). All participants will be randomly divided into control group and intervention&#xD;
      group in a ratio of 1:1. Phosphorus balance status is evaluated in participants of the&#xD;
      intervention group by the phosphorus balance calculator. Then, these participants will be&#xD;
      given individualized phosphate-binders, dietary and dialysis intervention according to the&#xD;
      results of phosphorus balance evaluation. Participants in the control group will not receive&#xD;
      the phosphorus balance status evaluation but receive phosphate-binder treatment according to&#xD;
      the KDIGO Guidelines. Dietary phosphorus intake, dialysate calcium concentration and dose of&#xD;
      active vitamin D, phosphorus-binders of all participants will be recorded during the whole&#xD;
      research program. After two-week treatment, the phosphorus balance of participants in&#xD;
      intervention group will be evaluated again and the therapeutic strategies then will be&#xD;
      adjusted. At the same time, the therapeutic strategies of participants in the control group&#xD;
      will be adjusted according to the serum phosphorus concentration. All participants will be&#xD;
      followed up for two weeks again and receive blood test and related examinations at the end of&#xD;
      study. The results of final examinations will be analyzed to evaluate the efficacy of&#xD;
      individualized treatment of hyperphosphatemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 29, 2019</start_date>
  <completion_date type="Actual">April 15, 2021</completion_date>
  <primary_completion_date type="Actual">January 3, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum phosphorus concentration</measure>
    <time_frame>Four weeks after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Achievement rate of serum phosphorus</measure>
    <time_frame>Four weeks after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum calcium concentration</measure>
    <time_frame>Four weeks after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum iPTH concentration</measure>
    <time_frame>Four weeks after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum albumin concentration</measure>
    <time_frame>Four weeks after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Maintenance Hemodialysis</condition>
  <condition>Hyperphosphatemia</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phosphate-binder intervention</intervention_name>
    <description>Use phosphate-binders according to KDIGO Guidelines, Chinese Guidance for Diagnosis and Treatment of Mineral and Bone Disorder in Chronic Kidney Disease and drug specification .</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Phosphorus-restricted dietary intervention</intervention_name>
    <description>Use low phosphorus diet and prolong the time of hemodialysis according to the phosphorus balance evaluation if necessary</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>Additional dialysis intervention</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject within 18-85 years old, male or female.&#xD;
&#xD;
          2. Subject receiving maintenance hemodialysis 3 times weekly at least 3 months with&#xD;
             autologous arteriovenous fistula.&#xD;
&#xD;
          3. Subject with hyperphosphatemia as defined by serum phosphorus concentration&#xD;
             &gt;1.45mmol/L.&#xD;
&#xD;
          4. Subject in a good general condition with a stable dietary habit.&#xD;
&#xD;
          5. Subject has insight of the disease and treatment himself/herself and haves ability to&#xD;
             communicate with others.&#xD;
&#xD;
          6. Subject has provided informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has residual renal function.&#xD;
&#xD;
          2. Subject with severe infection, anemia (Hb&lt;60g/L) or hypoproteinemia (Alb&lt;30g/L).&#xD;
&#xD;
          3. Subject has cancer or cachexia.&#xD;
&#xD;
          4. Subject with a history of myocardial infarction, coronary angioplasty, or coronary&#xD;
             arterial bypass grafting within the past 3 months.&#xD;
&#xD;
          5. Subject with severe hematopoietic system disease, such as aplastic anemia, thalassemia&#xD;
             and thrombocytopenic purpura.&#xD;
&#xD;
          6. Subject with severe gastrointestinal system disease such as dysphagia, hypohepatia,&#xD;
             Active gastrointestinal bleeding, ileus, enterobrosis, or received subtotal&#xD;
             gastrectomy.&#xD;
&#xD;
          7. Subject with disease which affects serum phosphorus concentration such as&#xD;
             hypoparathyroidism (iPTH&lt;11pg/ml), severe hyperparathyroidism (iPTH&gt;600pg/ml) and type&#xD;
             2 vitamin D dependence rickets.&#xD;
&#xD;
          8. Subject is pregnant.&#xD;
&#xD;
          9. Subject is currently enrolled in or has completed any other investigational device or&#xD;
             drug study&lt;30 days prior to screening, or is receiving other investigational agents.&#xD;
&#xD;
         10. Subject has inadequate hemodialysis with a recent spKt/V&lt;1.2.&#xD;
&#xD;
         11. Subject has a poor nutritional status with a recent (nPNA&lt;1.0g/kg/d) .&#xD;
&#xD;
         12. Subject is not a good participant for the research in the opinion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Huadong Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Chen Jing</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

